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The tumor specificity of JAA-F11, a novel monoclonal antibody specific for the Thomsen-Friedenreich cancer
antigen (TF-Ag-alpha linked), has been comprehensively studied by in vitro immunohistochemical (IHC) staining of
human tumor and normal tissue microarrays and in vivo biodistribution and imaging by micro-positron emission
tomography imaging in breast and lung tumor models in mice. The IHC analysis detailed herein is the
comprehensive biological analysis of the tumor specificity of JAA-F11 antibody performed as JAA-F11 is
progressing towards preclinical safety testing and clinical trials. Wide tumor reactivity of JAA-F11, relative to the
matched mouse IgG3 (control), was observed in 85% of 1269 cases of breast, lung, prostate, colon, bladder, and
ovarian cancer. Staining on tissues from breast cancer cases was similar regardless of hormonal or Her2 status,
and this is particularly important in finding a target on the currently untargetable triple-negative breast cancer
subtype. Humanization of JAA-F11 was recently carried out as explained in a companion paper “Humanization of
JAA-F11, a Highly Specific Anti–Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis”
(Neoplasia 19: 716-733, 2017), and it was confirmed that humanization did not affect chemical specificity. IHC
studies with humanized JAA-F11 showed similar binding to human breast tumor tissues. In vivo imaging and
biodistribution studies in a mouse syngeneic breast cancer model and in a mouse-human xenograft lung cancer
model with humanized 124I- JAA-F11 construct confirmed in vitro tumor reactivity and specificity. In conclusion,
the tumor reactivity of JAA-F11 supports the continued development of JAA-F11 as a targeted cancer therapeutic
for multiple cancers, including those with unmet need.
Translational Oncology (2018) 11, 450–466dress all correspondence to: Kate Rittenhouse-Olson, For-Robin, Inc, Buffalo, NY.
mail: krolson@buffalo.edu
o-first authors.
ceived 17 August 2017; Revised 10 January 2018; Accepted 16 January 2018
2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
cess article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tps://doi.org/10.1016/j.tranon.2018.01.008troduction
he Thomsen-Friedenreich pancarcinoma antigen (TF-Ag) has long
en established as a cancer-associated carbohydrate moiety, with cell
rface expression on cancers including those of the breast, colon,
ostate, bladder, and ovary [1–8]. Alterations in glycosylation in
alignant cells lead to the elevated surface expression of TF-Ag,
hich is normally cryptic due to glycan chain extensions [5,9,10].
eing tumor restricted and having a role in metastasis, TF-Ag is
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Translational Oncology Vol. 11, No. 2, 2018 Biological specificity of JAA-F11, an anti-TF-Ag antibody Karacosta et al. 451nsidered to be a promising molecule for cancer immunotherapy
,11–19]. However, previous attempts at therapy directed to this
rget have been limited due to specificity problems. The glycotope
ructure of TF-Ag (Galβ-3GalNAc-alpha) has been historically
tected and extensively studied with anti-TF sera as well as lectins,
imarily peanut agglutinin (PNA) [6,20–25]. However, PNA is not
clusively specific for the TF-Ag glycotope due to its ability to bind
terminal galactosyl residues on many commonly occurring
ycoproteins and glycolipids. PNA cannot distinguish between the
o TF-Ag anomeric linkage configurations, one of which is linked in
alpha (α) orientation (which is O-linked to serine/threonine
sidues and is the cancer associated form) from the beta (β)
ientation (which is primarily linked to glycolipids on the surface of
rmal cells) [24,26,27]. Due to the status of TF-Ag as a cancer
arker, many polyclonal as well as monoclonal antibodies have been
veloped towards the TF-Ag disaccharide [24,28–33]. However,
though most of these agents were in agreement for the
ncarcinoma expression of TF-Ag [2,8,34,35], they were disparate
ncerning normal tissue staining patterns [23,24,27,29,36]. This
uld be attributed to specificity issues towards the disaccharide’s
kage configuration (alpha vs beta), technical issues involving the
ss of sialylation on normal tissues, and the loss of Galβ1-3GalNAc
munoreactivity on cancer tissues created by tissue handling
ocedures [23,24]. Recently, the chemical specificity of humanized
rms of JAA-F11 has been characterized. JAA-F11 was humanized to
IgG1 in a manner which 1) retained the tumor-associated Galb1-
alNAc alpha specificity, 2) added antibody-dependent cellular
totoxicity activity, and 3) retained the ability to internalize for use as
antibody drug conjugate and added in vivo efficacy against a
man triple-negative breast cancer xenograft [37]. These promising
eclinical data are helping move JAA-F11 towards clinical trials, thus
creasing the importance of these immunohistochemical (IHC) and
aging studies.
To validate the clinical applicability of JAA-F11, the main
jective of this investigation was to immunohistochemically confirm
A-F11’s reported specificity when tested against a large number of
rious human cancer and normal tissue arrays. A significant
ortcoming to a comprehensive study of human tissue is that a
man antibody will create considerable background in indirect
tection methods using a secondary labeled anti-human IgG
tibody due to the presence of human IgG in human tumor and
rmal tissue samples. Therefore, mouse JAA-F11 was largely used to
reen multiple human cancer arrays due to concern regarding this
ckground issue. Nonetheless, a humanized variant of JAA-F11
JAA-F11) is most favorable for future therapeutic studies. To
rcumvent background issues with anti-human immunoglobulin, a
otinylated form of the hJAA-F11, H2aL2a, was used to confirm the
ouse JAA-F11 findings. Furthermore, the radiolabeled hJAA-F11
nstruct, H2aL2a, also showed high specificity for tumor binding in
veral in vivo mouse tumor models. Overall, our results support that
e JAA-F11 antibody and specifically its humanized derivative are
rong candidates for future human therapeutic studies on a wide
ray of human carcinomas.
aterials and Methods
munohistochemistry
All human tissue array slides were purchased from US Biomax
ockville, MD). The standard procedure at US Biomax for cancersues is to place tumor tissue in neutral pH buffer formalin 15 to 30
inutes after surgical resection for a 24-hour period. Previous data in
r lab have shown that fixation for longer than 24 hours results in a
ss of TF-Ag reactivity (data not shown), so the US Biomax cancer
mor tissue protocol is optimal for this work. Different criteria are of
cessity used for obtaining normal tissue, as these were for the most
rt obtained during autopsy. Autopsy can begin up to 6 hours after
ath and can take up to 6 hours, so the normal tissue may remain
resected up to 12 hours [38] after death before being placed into
rmalin; thus, some effects of in situ degradation may be observed on
ese tissues as opposed to tumor tissue. After fixation, tissues are then
aced into ethanol, followed by xylene and then paraffin. To process
e slides for IHC, slides were deparaffinized by passing them through
lene and then rehydrated through 100% ethanol, 95% ethanol,
% ethanol, and finally water. Slides were then subjected to antigen
trieval to expose cross-linked antigen using citrate buffer [10 mM
dium citrate (pH 6.0), 0.5% Tween-20] for 40 minutes in a
getable steamer, followed by a 20-minute cool-down. Slides were
ashed twice with Tris-phosphate wash buffer, and endogenous
roxidases were blocked with 3% hydrogen peroxide in methanol for
minutes. After another wash step, endogenous biotin was blocked
ith an avidin-biotin blocking kit (Thermo Scientific, Waltham,
A). Following blocking with a goat sera block (Vector Labs,
urlingame, CA), slides were incubated with either control mouse
G3 (Southern Biotech, Birmingham, AL) or JAA-F11 at 25 μg/ml
al concentration in goat serum for 1.5 hours. As mouse IgG3 is
one to self-aggregation, some preparations of JAA-F11 were used
at were partially purified only, thus containing a significant portion
bovine serum albumin (BSA) derived from media serum and
tained during the antibody purification. For these preparations, the
tal amount of JAA-F11 was determined using SDS-PAGE and
nsitometry, so the total amount of applied JAA-F11 was always
pt at 25 μg/mL final. Slides were washed and then incubated with
otinylated anti-mouse IgG antibody (Vector Labs, Burlingame,
A) for 30 minutes. Following washing, slides were treated using a
ectastain Elite ABC reagent (Vector Labs, Burlingame, CA) for 30
inutes, then washed and developed with ImmPact DAB chromagen
ector Labs, Burlingame, CA). Slides were counterstained with
odified Harris Hematoxylin (Richard-Allan Scientific), dehydrated,
d then mounted. Slides were scored as 0, 0.5, +1, +1.5, +2, +2.5, or
in a microscope (Zeiss) while viewing at 100×. A positive score was
e in which after subtraction of the IgG3 control from the JAA-F11
ore, the value was ≥1. Slides were scanned and images taken using
Aperio Scan Scope GL (Leica BioSystems). For IHC using
otinylated human antibodies, primary antibodies were used at 50
g/ml, an increase needed due to the absence of amplifying secondary
tibody, with other steps remaining the same.
Some slides had tissue cores that represented duplications
eviously tested on a different slide from the same patient’s tumor.
eplicate specimens were tabulated in the percentages only one time.
he screening of the tumor slides was verified using concordance for
oring of these replicates in breast, colon, bladder, prostate, and
ary arrays. The frequency of concordant scores was calculated by
alysis of duplicate, triplicate, or higher cases read by a scientist
inded to the presence of tissues from the same case in the different
rays. To tabulate the total score and the positive concordance score,
greater than 50% of sections were blindly scored as positive for
aining, then a positive score for this tumor was recorded; otherwise,
e patient’s tumor was considered negative. In the case of equal
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Table 1. Total Positive Staining of All Human Cancer Tissue Types by JAA-F11
Carcinoma Reactivity with JAA-F11
Cancer Type # Positive # of Cases % Positive
Breast 391 * 444 * 88%
Prostate 70 75 93%
Lung 197 * 235 * 84%
Colon 37 46 80%
Bladder 71 79 90%
Ovary 315 390 81%
total 1081 1269 85%
Immunohistochemically stained tissue arrays were scored as positive as detailed in Materials and
Methods.
* For breast and lung cancers, both the original tumor and the metastatic site were counted as separate
tumors, as several tissue arrays represented both types of tumors from the same patient.
Figure 1. Representative images of human breast cancer staining with
matched isotype mouse IgG3 (mIgG3) control (right). Staining is show
markers (triple negative, TN) (A, B), positive for ER and PR (ER+/PR+) (C,
(ER+/PR+/HER2+) (G, H), and normal breast tissue (I, J). Histological t
Magnification: 40×.
452 Biological specificity of JAA-F11, an anti-TF-Ag antibody Karacosta et al. Translational Oncology Vol. 11, No. 2, 2018mbers of positive and negative staining, then the case was removed
om the percentage positive analysis. The agreement of positive
ncordance from organ to organ was comparable, and the overall
tal average agreement of the scores for all replicate cases from the
erlaps was 89%. This verifies the validity of the scoring
ethodology, as well as the consistent judgment and scoring of the
ader, who was blinded to the presence of the replicates.
To further validate scoring, a pathologist served as an independent
cond reader and scored 863/1269 of the cores. The pathologist
mained blinded to the initial reader’s score until after his scoring.
he pathologist’s scores showed agreement with the principle scorer,
ith a 93.2% correlation of slides being scored positive or negative in
reement (Supplemental File 2).JAA-F11 antibody. JAA-F11 staining specificity (left) compared to
n for typed breast cancer markers: lacking the three common
D), positive for HER2 (HER2+) (E, F), positive for all threemarkers
yping into the ER/PR/HER2 groups was provided by US Biomax.
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Table 2. Positive JAA-F11 Staining in Specific Cases of Human Breast Cancer Samples
(A)
JAA-F11 Reactivity with Breast Cancer: ER, PR, & HER2 Subtypes
Type #Positive #Cases % Positive
Triple negative 118 126 94%
ER+ PR+ 56 62 90%
ER+ PR− 23 25 92%
PR+ ER− 19 19 100%
HER2+ 80 82 98%
(B)
JAA-F11 Reactivity with Breast Cancer by Stage
Stage # Positive # of Cases % Positive
I 15 20 75%
II 206 238 87%
III 69 76 91%
IV 3 3 100%
(C)
JAA-F11 Reactivity of Breast Tumors and Matching Lymph Nodes
Type # Positive # Of Cases % Positive
Tumors 44 46 96%
Lymph nodes 42 46 91%
(A) Positive JAA-F11 Staining in Breast Cancer Cases Broken Down into Type Based on
Overexpression of Specific Cellular Receptors. (B) Staining of Breast Cancer Samples Based on
Progressive Staging of the Breast Cancer Case. (C) Staining of Breast Cancer Tumor in Patients
That Also Had Metastasis to Lymph Nodes.
Translational Oncology Vol. 11, No. 2, 2018 Biological specificity of JAA-F11, an anti-TF-Ag antibody Karacosta et al. 453Preincubation IHC with Soluble TF-Ag-BSA for Inhibition of TF-
g Specific Staining. For analysis of the specificity of the staining
served, IHC was performed as above with the following modifica-
ns. One hour prior to addition of primary antibody to tissue samples,
A-F11 at 25 μg/ml was preincubated with either IHC grade BSA
ontrol) or TF-Ag-BSA (100-200 μg/ml) (inhibited) for 1 hour at
om temperature. Specific inhibition of JAA-F11 binding to TF-Ag
as confirmed using the preincubated JAA-F11 in enzyme-linked
munosorbent assays (ELISAs) against immobilized TF-Ag-BSA
here it was found to be decreased ≥75% compared to the BSA addition
ntrol. Preincubated JAA-F11 was then used in IHC experiments as
tailed before. The amount of inhibition of staining was then graded
ainst the BSA control, and the tissue was considered inhibited for JAA-
1 staining if the change in staining was ≥1. These inhibition scores are
esented in Supplemental File 3 and tabulated in Table 4b and c.
Preparation and Biotinylation of hJAA-F11 H2aL2a. The
aracterization of the hJAA-F11 H2aL2a has been detailed elsewhere
7]. Briefly, two vectors, encoding the heavy and light chains of
2aL2a, were transfected into the Chinese hamster ovary cell line
HO-K1 (ATCC, Manassas, VA). Stable cell lines expressing hJAA-
1 H2aL2a were selected using G418 and histidinol and confirmed to
nd to immobilized TF-Ag-α linked to BSA in an enzyme
munoassay [17,39]. hJAA-F11 H2aL2a was then purified using
rotein A Sepharose Fast Flow resin (GE Healthcare, Pittsburgh, PA),
llowed by Capto S ImpAct resin (GE Healthcare, Pittsburgh, PA).
Purified hJAA-F11 H2aL2a was dialyzed in 1× PBS and
otinylated using an ImmunoProbe Biotinylation Kit (Millipore-
gma, St. Louis, MO) according to the manufacturer’s protocol. The
me protocol was used to also biotinylate a matched human IgG1yeloma protein (Fitzgerald, Acton, MA). The ability of biotinylated
AA-F11 H2aL2a to recognize TF-Ag-BSA was confirmed using
LISA probed with streptavidin linked to alkaline phosphatase.
ntibody purity was determined using SDS-PAGE to confirm that
ere was no change in antibody structure such as cross-linking or
gradation following modification. Concentrations were determined
ing A280 absorbance as well as a BioRad protein concentration
agent (BioRad, Hercules, CA).
adiolabeling of hJAA-F11 H2aL2a via the Bolton-Hunter
ethod
The indirect radioiodination of the hJAA-F11H2aL2a antibody was
rformed using the indirect Bolton-Hunter method as described
rlier [13,40,41]. One hundred micrograms of N-succinimidyl-3-(4-
droxyphenyl propionate) (SHPP) (Thermo Scientific, USA) was
ded to 2 mg of hJAA-F11 H2aL2a (10 mg/ml in sodium borate
ffer) and incubated on ice with mixing once every 30 minutes for 3
urs. Nonreacted SHPP was removed by dialysis against Tris buffer
.125M Tris•HCl, pH 6.8, 0.15 MNaCl). The indirect method was
ilized to label lysines rather than the direct method which labeled
rosines and resulted in a loss of reactivity likely due to the number of
rosines in the CDRs. The product of the reaction was quantitated by
ioRad protein assay and analyzed to determine maintenance of in vitro
tigen binding against TF-Ag-BSA by ELISA [12,13].
Four to seven mCi of 124I in 0.02 M of sodium hydroxide (IBA
olecular North America Inc., VA, USA) was directly added to the
ecoated iodination tube (Thermo Scientific, USA), and the SHPP
ked H2aL2a was mixed with sodium borate buffer (pH 8.5,
0mM) and incubated in the iodination tube at room temperature
r 6 minutes. The reaction was stopped by adding 50 μl of
avenging buffer (10 mg tyrosine/ml in Tris iodination buffer). The
diolabeled antibody in the reaction mixture (~2 mg) was isolated
ing a Dextran Desalting Column (Thermo Scientific, USA) with
ris/NaCl/EDTA buffer as the elution buffer. The activity of each
action was measured using a Capintec Radioisotope Calibrator,
RC-12. The purity of each fraction was determined by HPLC. The
4I-hJAA-F11 H2aL2a was analyzed for its TF-Ag binding activity
radioimmunoassay to ensure that no loss of reactivity towards the
F-Ag occurred due to radiolabeling [13].
nimals and Tumor Models
Female BALB/c mice (Harlan, Madison, WI), 8 to 10 weeks of age,
ere used in micro-positron emission tomography (PET) imaging
d biodistribution analysis of 4T1 breast tumors. All mice were
used in accordance with the Institutional Animal Care and Use
ommittees regulations in an Association for Assessment and
ccreditation of Laboratory Animal Care International Accredited
cility (University at Buffalo), IACUC#CLS01122Y. All mice were
vided into two groups: group I with tumor-bearing mice and group
with non–tumor-bearing mice. 4T1 murine breast cancer cells were
planted by injecting 2.5 × 104 cells in 100 μl of Dulbecco’s
osphate-buffered saline subcutaneously under the right nipple
hile mice were anesthetized with isoflurane/oxygen. Mice were
ven cold potassium iodide water (0.2 g/l, ad libitum in their
inking water to block thyroid uptake of 124I) and rabbit
munoglobulin (3 mg/mouse, to block Fc receptor uptake) prior
injection of the radiolabeled antibody. Potassium iodide was then
ven in water for the entire duration of the experiment starting 3 days
ior. Mice were administered radiolabeled 124I-hJAA-F11 H2aL2a
(4
da
de
ad
by
af
ca
in
fla
B
de
m
m
C
T
tr
po
be
Figure 2. Representative JAA-F11 antibody staining of matched human breast cancer with metastatic lymph nodes. Two representative
cases from two patients with invasive ductal breast carcinoma with pathologic diagnosis as documented by US Biomax are shown. Case
1 (A-D) and case 2 (E-H) are shown with JAA-F11 staining specifically (left) compared to matched isotype mIgG3 control (right). Each case
was compared for the original breast carcinoma to themetastatic lymph of each patient (A, B to C, D and E, F to G, H). Magnification: 40×.
Figure 3. JAA-F11 reactivity with breast cancer by stage. Total JAA-
F11 reactivity (percent of cases with positive JAA-F11 staining)
plotted relative to increasing breast cancer stage. JAA-F11
reactivity is positively correlated with more advanced breast cancer
stage.
454 Biological specificity of JAA-F11, an anti-TF-Ag antibody Karacosta et al. Translational Oncology Vol. 11, No. 2, 20180 μg of antibody in 100 μl of Tris buffer) by tail vein injection at 14
ys following tumor cell administration and were analyzed to
termine biodistribution and micro-PET imaging. The total
ministered radioactivity for each individual mouse was determined
measuring the 124I-hJAA-F11 H2aL2a loaded syringes before and
ter injection with a CRC-12R dose calibrator.
For the human lung tumor xenograft imaging study, human lung
ncer cells HTB-171 (NCI-H466, ATCC) were implanted by
jecting 8 × 106 cells in 100 μl of DPBS subcutaneously in the left
nk of 8- to 10-week-old female nude mice (Jackson Laboratories,
ar Harbor, ME). The remainder of the protocol follows that as
scribed above.
icro-PET Imaging
For whole body imaging of tumor-bearing mice, a Focus 120
icro-PET camera (Siemens Concorde Microsystems previously CTI
oncorde Microsystems) was used as previously described [12,13].
he emission scan window was set between 350 and 750 keV. The
ansmission scan of some mice was also performed using a Cobalt-57
int source for 9 minutes. The transmission scan window was set
tween 120 and 125 keV. Analysis of the acquired data and image
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Figure 4. Representative images of human lung cancer staining with JAA-F11 antibody. JAA-F11 staining specificity (left) is compared to
matched isotype mouse IgG3 (mIgG3) control (right). Staining is shown for lung cancers as categorized by US Biomax. The most common
lung cancer types were selected: adenocarcinoma (A, B), squamous cell carcinoma (C, D), small cell carcinoma (E, F), and large cell
carcinoma (G, H). Staining of normal lung tissue is shown in (I, J). Magnification: 40×.
Translational Oncology Vol. 11, No. 2, 2018 Biological specificity of JAA-F11, an anti-TF-Ag antibody Karacosta et al. 455construction using filtered back projection 2D were done using the
ftware micro-PET manager 2.2.4.0. Before scanning, the mice were
esthetized with oxygen/isoflurane (2% induction, followed by 1%
aintenance isoflurane) and placed in the prone position in the
ntry of the micro-PET scanner. To analyze and localize the tumor
sed on metabolic rate, the radiolabeled glucose analog 18F-
orodeoxyglucose (FDG) was used as a positive control. A 20-
inute scan was performed for the 18F-FDG (IBA Molecular North
merica Inc., VA, USA) images. Three mice with tumors and one
ithout a tumor were selected and imaged 90 minutes after injection
18F-FDG (10.8-61.2 MBq). One day after FDG imaging, 580.9 to
01.2 MBq of 124I-hJAA-F11 H2aL2a was injected into 12 mice
ith tumors and 9 without, and micro-PET imaging was performed
48, 72, 96, and 168 hours on the mice that had been imaged with
e 18F-FDG. The mice were scanned for 30 minutes to obtain
ages.iodistribution and Tumor Uptake Studies
Following imaging at 48, 72, 96, and 168 hours, three mice in each
oup were sacrificed by injecting 0.1 ml sodium pentobarbital (Fatal
us) intraperitoneally. Blood, muscle, liver, lungs, kidneys, spleen,
art, stomach, large and small intestines, brain, and tumor tissue
ere weighed, and the amount of radioactivity was quantified in the
mma-counter with appropriate calibration. Radioactivity uptake
as calculated as the percentage of the injected dose per gram of tissue
ID/g). The total applied radioactivity was determined as above.
he percentage of injected dose (%ID) was corrected for decay
ilizing two accompanying standards at the time of each
odistribution.
esults
ur previous studies of JAA-F11 were carried out in a murine breast
mor model to confirm the feasibility JAA-F11 as a breast cancer
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Table 3. Positive Staining of Specific Lung Cancer Cases with JAA-F11
(A)
JAA-F11 Reactivity by Lung Cancer Type
Pathology # Positive # Of Cases % Positive
Adenocarcinoma 52 75 69%
Large cell carcinoma 13 16 81%
Squamous cell carcinoma 50 52 96%
Small cell carcinoma 37 38 97%
(B)
JAA-F11 Reactivity of Malignant Lung Cancer By Gender
Sex # Positive # Of Cases % Positive
Male 132 155 85%
Female 41 48 85%
(C)
JAA-F11 Reactivity of Lung Tumors and Matching Lymph Nodes
Type # Positive # Of Cases % Positive
Tumors 20 28 71%
Lymph nodes 22 28 79%
(A) Percentages of TF-Ag–Positive Staining Lung Cancers Broken Down by Lung Cancer Cell
Types. (B) JAA-F11 Staining of Lung Cancer Cases According to Known Genders. (C) Staining of
Lung Cancer Tumors in Patients That Also Had Metastasis to Lymph Nodes.
456 Biological specificity of JAA-F11, an anti-TF-Ag antibody Karacosta et al. Translational Oncology Vol. 11, No. 2, 2018erapy. JAA-F11 binds the murine breast cancer cell line 4T1 and
man breast cancer cell lines; increases mice survival; and prevents
etastasis of breast, prostate, and colon cancer cells through binding
TF-Ag in vivo and in vitro [12,17,18,42–45]. Other studies have
ggested that TF-Ag could be present on up to 80%-90% of human
ncers [22,46–50]. To comprehensively assess the potential of JAA-
11 to selectively target a wide range of different human cancer types,
e present study used IHC to screen an extensive panel of human
mor and normal tissues.
Human cancer tissue microarrays were obtained from US Biomax
ockville, MD) and evaluated using a paired murine IgG3 negative
ntrol microarray slide in IHC. Several cancer types were selected,
cluding cancers of breast, lung, ovary, colon, prostate, and bladder.
ositive tissue reactivity with JAA-F11 was found for 85% of all
dividual carcinoma cases tested (n = 1269) after subtracting the
nspecific staining score with the IgG3 control from the JAA-F11
ore. Breast, prostate, and bladder cancer cases were ~90% reactive
ith JAA-F11, while lung, colon, and ovarian cancer cases were ~80%
85% reactive with JAA-F11 (Table 1). The high amount of
sitive IHC staining with all tested carcinoma cases demonstrates
e prevalence of JAA-F11 binding TF-Ag on a wide array of human
ncer cells.
For breast cancer cases, the expression of the estrogen receptor (ER),
ogesterone receptor (PR), and/or the human epidermal growth factor
ceptor 2 (HER2) makes these tumors receptive to common targeted
erapies available today. However, tumors with the absence of the
pression of these receptors, triple-negative breast cancer or TNBC,
present the most aggressive and hardest to specifically treat breast
ncers, which rely largely on chemotherapy regimens. Breast cancer
icroarray slides with all types of breast cancers were screened using IHC
ith JAA-F11 and a matched mouse isotype IgG3 control (Figure 1,
able 2A). JAA-F11 strongly stained all types of breast cancer, includingNBC (Figure 1, A-B). Representative normal breast tissue without
aining reactivity is also shown (Figure 1, I-J). Table 2A summarizes
e human breast cancer array data by cancer subtype, including TNBC
R−/PR−/HER2−), ER+/PR+, ER+/PR−, PR+/ER−, and HER2+
ses. JAA-F11 was extremely effective at binding to all of these breast
ncer subtypes, including 94% of the 126 cases of TNBC, a tumor type
at currently has no targeted therapy. Breast tumor types that were
derrepresented are not shown in the table [e.g., ER+, PR+, andHER2+
nown as triple positive) were less than 3% of specimens]. Some of the
east cancer cases were not stratified by receptor status; therefore, the
act percentage positive shown varies slightly from Tables 1 to 2A.
Breast tumor staging information was also provided in the majority
the cancer tissue arrays. Stratifying by cancer stage, the summary
ta in Table 2B show that stage I breast cancer cases were 75%
sitive, stage II 87%, stage III 91% and that 100% of the stage IV
mples reacted with JAA-F11 antibody, showing a positive
rrelation with metastatic tendency (Table 2B and Figure 2).
me of the tissue arrays also contained patient matched lymph node
etastases (Figure 3 and Table 2C), where reactivity to primary
mors and the metastases was consistently similar. This indicates that
th the original tumor and its metastatic site tumor retained TF-Ag
pression.
The most common cause of cancer-related death is lung cancer;
erefore, the ability of JAA-F11 to bind lung cancer types was also a
cus of this IHC analysis. The lung tumor reactivity data were
ratified by cancer type into the major groups of small cell lung
ncers (SCLCs) and the non–small cell lung cancers (NSCLCs),
hich include adenocarcinomas, squamous cell carcinomas, and large
ll carcinomas (Figure 4 and Table 3A). Of the NSCLCs, squamous
ll carcinomas had the highest percentage of TF-Ag reactive samples
ith 96% of the 52 samples being positive. Sixty-nine percent of the
cases of NSCLC adenocarcinomas were reactive. The NSCLCs
tegorized as large cell carcinomas showed consistent TF-Ag
activity, with an 81% positivity rate for the 16 tumors that were
sted, but displayed an overall lighter staining than other lung
ncers. Ninety-seven percent of the 38 cases of SCLCs were positive.
oncerning analysis of gender differences, the proportion of tumor
ssues in the tested tissue microarrays with male compared to female
ses was slightly higher than the natural lung cancer prevalence
cording to the CDC. Our sample consisted of 76.3 % men, while
en with lung cancer will account for 52.6 % of all lung cancer cases
1]. Table 3B, stratified by gender, shows similar TF-Ag reactivity
oth 85%) in male and female cases of lung cancer. Some of the
ides also contained matching lymph node metastases (Table 3c), in
hich the binding of JAA-F11 to primary tumors and the matched
etastases was similar. This is in agreement with the breast cancer
etastatic lymph node data (Figure 2C) and confirms that the TF-Ag
pression in lung cancer was retained following tumor metastasis.
Ovarian cancer represents one of the highest mortality rates of
male cancer types, having a less than 50% survival rate within 5
ars of diagnosis, making it a good candidate for new targeted
erapies. Various types of ovarian cancers from 390 cases were
alyzed using JAA-F11. Similar to other types of cancers that were
sted, JAA-F11 was able to specifically stain 81% of cancer cases of
arian origin (Table 1). These included many cases of adenocarci-
mas (Figure 5), as well as other tumor types such as yolk sac tumors
d teratomas, with little staining on normal ovary cells.
Other carcinoma types were also analyzed using JAA-F11, including
adder, colon, and prostate. After breast and lung cancers, prostate and
Figure 5. Representative images of human ovarian cancer staining with JAA-F11 antibody. Staining with JAA-F11 and matched isotype
mouse IgG3 (mIgG3) control was performed on cancer and normal tissue for various ovarian cancer types (A-F) and for normal ovarian
tissue (G, H). Magnification: 40×.
Figure 6. Representative images of human colon, prostate, and bladder cancer staining with JAA-F11 antibody. Staining with JAA-F11 and
matched isotype mouse IgG3 (mIgG3) control was performed on cancer and normal tissue for bladder [cancer (A, B) and normal (C, D)],
prostate [cancer (E, F) and normal (G, H)] and colon [cancer (I, J) and normal (K, L)]. Magnification: 40×.
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Table 4. Staining of Normal Human Tissues by JAA-F11 and Effect of Preincubation with TF-Ag-
BSA
(A)
Normal Tissue Showing No Staining Using JAA-F11
Tissue % Reactive
Bronchus 0% (0/1)
Diaphragm 0% (0/1)
Eye 0% (0/3)
Intestine 0% (0/2)
Lymph 0% (0/5)
Nerve 0% (0/2)
Parathyroid 0% (0/2)
Salivary 0% (0/2)
Thymus 0% (0/5)
Thyroid 0% (0/7)
(B)
Normal Tissue With Nonspecific Staining Using JAA-F11
Tissue % Reactive Inhibitable With TF-Ag
Adrenal 88% (7/8) -
Bladder 25% (2/8) -
Bone 38% (3/8) -
Breast 19% (5/26) -
Cerebellum 43% (3/7) -
Cerebrum 21% (4/19) -
Colon 41% (7/17) -
Esophagus 88% (7/8) -
Heart 29% (2/7) -
Hypophysis 38% (3/8) -
Kidney 25% (2/8) -
Larynx 25% (1/4) -
Lung 10% (10/98) -
Ovary 16% (6/38) -
Prostate 50% (13/26) -
Skeletal Muscle 25% (1/4) -
Skin 71% (5/7) -
Spleen 22% (2/9) -
Testis 80% (4/5) -
Tongue 33% (1/3) -
Tonsil 50% (4/8) -
Uterus 25% (2/8) -
Table 4c
Normal Tissue With Inhibitable Staining Using JAA-F11
Tissue % Reactive Inhibitable With TF-Ag*
Pancreas 63% (5/8) +
Stomach 57% (4/7) +
Liver 44% (4/9) +
(A) Normal human tissue types that did not display staining in the presence of mJAA-F11 based on
all data presented in Supplemental File 1. (B) Normal human tissue samples that displayed some
degree of nonspecific staining with JAA-F11. Percentages are based on total positive samples from
Supplemental File 1. Each tissue was observed in experiments involving preincubation with TF-Ag-
BSA detailed in Supplemental File 3, and no inhibition of staining was observed, indicating that
staining seen was nonspecific. (C) Normal human tissue samples that displayed some specific
inhibition of JAA-F11 staining using soluble TF-Ag-BSA. The total reactive tissues are derived from
multiple samples from Supplemental File 1. Each tissue was observed in experiments involving
preincubation with TF-Ag-BSA on the same slides as those tissues in B. Specific inhibition
percentages are displayed in Footnotes. All of the pancreas samples showed inhibition of staining,
indicating that specific staining was seen in all samples. With stomach and liver, only some of the
samples showed specific inhibition of staining.
458 Biological specificity of JAA-F11, an anti-TF-Ag antibody Karacosta et al. Translational Oncology Vol. 11, No. 2, 2018lorectal cancers are the third and fourth most common cancers in the
nited States, according to the NCI (https://www.cancer.gov/types/
mmon-cancers). As seen with breast and lung cancers, JAA-F11
owed a distinct, selective staining on cancer cells from 90% of the casesbladder, 80% of colon, and 93% of prostate cancer cases (Table 1 and
gure 6), with little to no staining on surrounding normal tissue.
As any therapeutic treatment that relies on the specific targeting of
e antibody to only cancer cells and not to normal tissues, the ability
mouse JAA-F11 to not bind to and stain normal human tissue
rays was extensively investigated. It should be noted that the normal
ssue arrays that were obtained consisted of cadaver-derived tissue
ther than the normal adjacent tissue that accompanied the cancer
rays detailed above which are rapidly fixed after surgical resection.
he cadaver normal tissue harvesting can begin up to 6 hours after
ath and take an additional 6 hours before harvesting is complete.
dditionally, the appearance of some of the normal tissue on these
ides showed some changes consistent with autolysis including
graded-looking tissue and pale or absent nucleus in the cells.
herefore, we considered the possibility of alterations occurring in
ese normal tissues. In a total of 35 different normal tissue tested, no
aining was observed in 9 tissue types (Table 4A), 22 tissue types
owed light staining (Table 4B) that was weaker than the staining
served in tumor (Figure 7, A-X), and 4 tissues showed strong
aining and these included the esophagus (on Table 4B), pancreas,
omach, and liver (Table 4C). Normal tissue arrays which had better
ssue integrity showed consistently lower overall background staining
d in the majority of cases presented no staining. Staining, when
tected, was noted in areas such as stratified squamous epithelia (e.g.,
ophagus), glandular structures and/or secretions (e.g., adrenal
and, pancreas, stomach), testis, and pancreatic islet cells, as well as
ht staining in areas that would not be therapeutically accessible
.g., cerebrum) (Table 4). To determine whether this was specific or
nspecific reactivity of the normal tissue, a preincubation of the
tibody preparation with TF-Ag-BSA to remove the specific JAA-
11 antibody reactivity was performed, and this preparation was used
both tumor and normal tissue arrays. To determine the efficacy of
is preincubation, the pretreated antibody was tested on arrays
ntaining tumor sections. Prior to addition of JAA-F11 to a prostate
mor array, JAA-F11 was preincubated with either IHC grade BSA
TF-Ag-α linked to BSA. TF-Ag-BSA is routinely utilized as a
ating antigen to test JAA-F11 via ELISA assays [17,52]. In this
tuation, JAA-F11 is blocked by the added TF-Ag and expected to be
able to bind TF-Ag presented on the tumor arrays. Remaining
aining following preincubation with TF-Ag-BSA was considered to
nonspecific. Testing through ELISA confirmed that binding to
ate-bound TF-Ag-BSA was reduced 75% when JAA-F11 was
eincubated with TF-Ag-BSA in solution (data not shown). When
A-F11 was preincubated with BSA only, ELISA reactivity
mained, and strong staining of prostate tumor cells was observed,
hile preincubation with TF-Ag-BSA at the same concentration
eatly diminished tumor staining, confirming the efficacy of the
eincubation and the specific reactivity of JAA-F11 with TF-Ag on
mor tissues (comparison shown in Figure 8). For the prostate cancer
ray subjected to TF-Ag-BSA preabsorption, the amount of positive
aining prostate cancer samples that were inhibited was 98% (58/59
sitive cases; Supplemental File 3). When this TF-Ag preincubated
A-F11 was utilized on a normal autopsy tissue array, JAA-F11
aining was reduced only in the pancreatic islet cells (100% of
mples), stomach gastric cells (50% of samples), and hepatic cells
5% of samples)(Figure 9 and Table 4C), suggesting that the staining
cells of these normal tissues is specific in these cases, whereas the
served staining in all the other normal tissue types (where staining was
t reduced) is nonspecific (Figure 10 and Table 4B). Further
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Figure 7. Representative images showing little to no staining on human normal tissues with JAA-F11 antibody. Staining with JAA-F11 and
matched isotype mouse IgG3 (mIgG3) control was performed on multiple normal human tissues (A-X). Magnification: 40×.
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ncer array and two more normal human tissue arrays to fully determine
e extent and specificity of mouse JAA-F11 staining in vitro. The cancer
ray showed the same trend that was seen in the prostate cancer array,
ith 73% of carcinomas showing TF-Ag–dependent specific inhibition
llowing preincubation with soluble TF-Ag-BSA (Supplemental File 3).
his array also displayed inhibition of other cancers outside of the scope of
is study including thyroid, pancreas, and testis. The normal tissue arrays
ne in parallel showed almost no inhibition of staining following
eincubation, again showing that the observed IHC staining of most
rmal tissue is nonspecific. In one of these additional arrays, one
ecimen (n=1) of fallopian tube, a previously untested tissue, was tested
d the light staining it exhibited was inhibitable. This inhibition will be
vestigated in future studies due to its low sample number in this study
upplemental File 3).
To determine if IHC staining would be improved by investigating the
aining potential using the recently characterized hJAA-F11H2aL2a [52],
IHC assay was designed using biotinylated hJAA-F11 to circumvent
oblems using a secondary labeled anti-human immunoglobulin on
man tissue. Using a biotinylated human myeloma IgG1 protein as a
atched control, the staining of biotinylated hJAA-F11 H2aL2a was
sessed against a human breast cancer array and a normal human tissue
ray. This stainingwas also compared against that of normal human tissue
aining using the mouse JAA-F11 done in parallel. Like the originalouse antibody (Figure 1), biotinylated hJAA-F11 H2aL2a was able to
ecifically stain human cancer cells in the breast cancer array, including
ses that were ER+/PR+ and TNBC, while there was little to no staining
ith the biotinylated human IgG1 (Figure 11,A-D). Importantly, several
rmal human tissues which had shown high backgrounds with the
ouse antibody including esophagus and kidney (Figure 10) showed
arkedly lower background staining using the biotinylated human
tibody, while retaining the ability to stain the breast cancer cells
igure 11). As the humanization of JAA-F11 is required for therapy
ith JAA-F11, these data confirm the potential of hJAA-F11 H2aL2a
en in vivo efficacy studies [37].
To evaluate the biodistribution properties of hJAA-F11 H2aL2a,
F-Ag–positive 4T1 murine breast tumors were established in female
alb/C mice as described earlier [17]. Biodistribution analysis was
rformed in tumor-bearing (n=12) and non–tumor-bearing (n=9)
ice. One day before the 124I-hJAA-F11 H2aL2a injection, the
etabolic marker 18F-FDG was administered for positive control for
mor localization. In tumor-bearing mice, localization of 18F-FDG
as observed in high metabolic areas including tumor with high uptake
shown in Figure 12A. In the non–tumor-bearing mice, 18F-FDG
take was seen in only high metabolic areas (data not shown).
Three tumor-bearing mice and one non–tumor-bearing mouse were
aged at 48, 72, 96, 144, and 168 hours after 124I-hJAA-F11H2aL2a
jection. The specificity of binding to TF-Ag on tumor cells was
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Figure 8. Representative images of JAA-F11 antibody staining on human prostate cancer tissue with or without preabsorption with TF-
antigen. Three cases of human prostate cancer are shown (A-F) with JAA-F11 staining without TF-antigen (only BSA) (left) or with
preincubation with TF-antigen (TF-Ag-BSA) (right). Images (A-F) confirm specific TF-Ag staining on prostate cancer. Images (I, J) show no
staining on normal prostate tissue. Magnification: 40×.
460 Biological specificity of JAA-F11, an anti-TF-Ag antibody Karacosta et al. Translational Oncology Vol. 11, No. 2, 2018idenced by the observed high uptake of 124I-hJAA-F11 H2aL2a in
e tumor of the 4T1 tumor-bearing mice and lack of reactivity in the
n–tumor-bearing mouse (Figure 12, C versus D). At 48 hours, high
ckground signal from normal tissues such as heart and lungs was
served alongwith specific imaging of the tumor due to the presence of
beled antibody in the blood. However, at this time point, 124I-hJAA-
11 H2aL2a uptake in the tumor was significantly higher than
ckground, allowing clear imaging of the tumor (Figure 12C). By 72
urs, average tumor uptake of 124I-hJAA-F11 H2aL2a determined by
ssue distribution was 5.0±1.36%ID/g and represented the highest
ount of radiolabel of all analyzed tissues with the exception of blood
igure 13). Uptake of 124I- hJAA-F11 H2aL2a increased slightly to
out ~5.7% ID/g, which persisted to the last imaging time point taken
7 days postinjection. Average uptake of the 124I-hJAA-F11 H2aL2a
the heart, liver, and muscle decreased to 0.05, 0.5, and 0.2%ID/g
spectively at 168 hours (Figure 13 and Supplemental Table 1). Note
at the high blood levels in the early time points in Figure 13 result in
e heart and lung hot spots in the early time points in the imaging
igure 12). This is consistent with the biodistribution results seen by
hers with radiolabeled whole antibody [53–55]. Note that all tissues
cept tumor and kidney have parallel decreasing lines in Figure 13,dicating that no specific tissue accumulation is occurring. Kidney
ansiently increases slightly due to the fact that it is a clearing site of free
4I, while the amount in the tumor as a % of injected dose increases at
ch time point (Figure 13). 124I-hJAA-F11 H2aL2a in the non–
mor-bearing mice did not show significant or specific uptake. By 144
urs, no radiolabeled signal was observed in controlmice as shown in the
gure 12D control panel. Importantly, these in vivo organ imaging and
odistribution studies with 124I- hJAA-F11 H2aL2a at 7 days support
e IHC findings that the hJAA-F11 H2aL2a has negligible binding to
rmal tissues.
To further expand the applicability of hJAA-F11H2aL2a in an in vivo
odel, HTB-171 (NCI-H446) human lung cancer cells were injected
to female nude mice in a study consisting of only PET imaging. Once
mors were palpable on day 18 postinjection, 124I-hJAA-F11 H2aL2a
as injected into mice, and localization was tracked as in the prior
periment. As with the breast cancer murine model, 124I-hJAA-F11
2aL2a was found to specifically target the lung tumor in the nude
ouse model and persist in the tumor for at least 7 days (Figure 12D). In
nclusion, our results showed that 124I-hJAA-F11H2aL2a antibody is a
perior in vivo imaging agent because of low nonspecific uptake and
ecific tumor-to-soft tissue contrast.
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Figure 9. Images of JAA-F11 antibody staining on normal human tissue with or without preincubation with TF-antigen. A representative
prostate cancer case (A-B) and four types of human normal tissue are shown (C-J) with JAA-F11 staining without TF-antigen (only BSA)
(left) or with preincubation with TF-Ag-BSA (right). Images A and B confirm specificity of TF-Ag staining on prostate cancer, similar to that
shown in Figure 8. Specific, inhibitable staining of specific cells was seen in only normal pancreas, stomach, and liver tissue since the TF–
Ag positive cells were decreased upon preincubation with TF-Ag-BSA (D, F, H). Conversely, colon cells do not show any significant
staining with JAA-F11 either in the presence or absence or free TF-Ag (I, J). Magnification: 80×.
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argeted therapies for cancers are becoming an increasingly
portant facet of anticancer strategies. As such, there is a great
met need for a generalized pancarcinoma marker that can be the
sis of such a strategy. Antibody-based therapies such as trastuzumab
reast cancer) and necitumumab (squamous non–small cell lung
rcinoma) have shown the power of such avenues but are limited to
ncer cell surface markers (HER2/neu and EGF receptor,
spectively) that are not overexpressed in the majority of cases.
ere the specificity of the anti-TF-Ag antibody JAA-F11 and its
manized derivative hJAA-F11 H2aL2a is described in detail,
cumenting their specific abilities to selectively bind human tumor
lls of many types including breast, prostate, lung, colon, bladder,
d ovarian cancers.Since the initial discovery of the tumor association of TF-Ag over
years ago, many studies have attempted to use the tumor cell
ecific exposure of the core antigen for production of antibodies
pable of detecting TF-Ag [30,31,33,56]. However, the consistent
oblem with these attempts has been the lower specificity of these
rategies; wherein the beta linked version of TF-Ag is recognized
ong with the alpha linked anomer, as well as other elongated or
anched carbohydrates found on normal tissues. Additionally,
omising antibodies against TF-Ag, such as HH8 [31] and A78-
/A7 [30], are of the mouse IgM isotype, further limiting the
tential for theranostic approaches.
The best known earlier anti-TF strategy that made it to Phase III
udies is the anti-TF mAb 170H.82 (known as the trademark Tru-
int). This antibody was withdrawn during human trials, likely due to
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Figure 10. Images of JAA-F11 antibody staining on normal human tissue with or without preincubation with TF-Ag-BSA. Several
representative images are shown for tissue types that have a propensity to display background staining with JAA-F11, either with or
without TF-Ag preincubation. Three types of human normal tissue are shown (A-F) with JAA-F11 staining without TF-antigen (only BSA)
(left) or with JAA-F11 preincubation with TF-antigen (TF-Ag-BSA) (right). These tissue types show a similar degree of staining either in the
presence or absence or free TF-Ag (B, D, F), suggesting that these normal tissues show nonspecific staining. Magnification: 80×.
462 Biological specificity of JAA-F11, an anti-TF-Ag antibody Karacosta et al. Translational Oncology Vol. 11, No. 2, 2018s nonselective binding to both TF-Ag-α and TF-Ag-β structures
sulting in off-target binding and accumulation in the kidney or liver
7,58]. Radiolabeled PNAwith its binding to bothTF-Ag anomers and
sultant lack of specificity also showed kidney binding on imaging [59].
Here, we extensively documented the ability of the original mouse
A-F11 to specifically bind to and stain 85% of tumor tissue from
69 cases of various types of human cancers, while on the analysis of
normal human tissues, 32 of these tissues did not show specific
aining. Specific staining was found only on pancreatic islet cells,
omach gastric cells, and hepatic cells (Table 4). It is our hypothesis
at staining of these tissues with high enzymatic activity was an
tifact of the use of partially autolyzed normal tissues from cadavers.
was reported by Philipsen et al. [60] that cell membrane TF-Ag was
sent in 15 of the 15 human pancreas samples that they obtained
rgically and immediately fixed. However, they also showed that
on neuraminidase treatment, TF-Ag was revealed after exposure by
eatment with Clostridium perfringens type X neuramindase in all
mples [60]. Clostridium perfringens neuraminidase cleaves α 2-3, α
6, and α 2-8 linked sialic acid. The normal pancreata used in the
C in this study, unlike those in the Philipsen study, were obtained
autopsy which began up to a period of up to 6 hours postmortem
d took up to 6 hours [38], leaving significant time for autolysis (up
12 hours). The pancreas is one of the first organs to undergo
tolysis, with autolysis of this organ occurring within hours after
ath [61]. Supporting our hypothesis is the fact that the pancreas is
ghest in expression of Neu1, a neuraminidase that cleaves both α 2-
and α 2-6 linked sialic acids [62]. Thus, the Philipsen reports of
uraminidase [60] exposing TF-Ag in normal pancreas and the
onti review [63] describing the high Neu1 expression in thencreas support our hypothesis that TF-Ag could become exposed
these tissues. Similar theories could be developed for the staining
the normal human liver and stomach samples since these are both
gans with enzymatic activity and are among tissues prone to early
tolysis [61,64–66]. In addition, liver has a high expression level of
otin, which is commonly problematic in the ABC staining
chniques such as utilized here [67], and hepatocytes have high
pression of asialoglycophorin receptors [68], which may have
und TF-Ag present. In contrast to normal tissues, tumor tissue has
en obtained at surgery and is rapidly fixed and thus would not be
pected to show autolytic changes. The mouse liver and the stomach
not have increased levels of 124I JAA-F11 in our imaging and
odistribution studies (Figures 12 and 13), substantiating this
pothesis; however, the pancreas had not been collected in this or
y of our previous biodistribution studies. Overall, although
ggestive, since our studies cannot conclusively state that there is
possibility of specific binding occurring with the pancreas,
omach, and liver, these organs should be carefully assessed in animal
fety analysis and in subsequent Phase I clinical trials.
The recently developed and characterized humanized IgG1 form of
A-F11, hJAA-F11 H2aL2a [52], was biotinylated and displayed the
ility to specifically stain human breast cancer while also having a
wer general nonspecific background on normal tissue compared to
e mouse antibody. These results confirm the findings of our
hibition analysis, suggesting that some specific staining was present
ly on these autopsy specimens of human pancreas, stomach,
d liver.
hJAA-F11 H2aL2a and other humanized constructs, which are
manized IgG1 molecules, are designed for immunotherapy and
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Figure 11. Biotinylated hJAA-F11 H2aL2a exhibits specific staining on human breast cancer but not normal esophagus or kidney. Human
breast cancer cases of ER+/PR+ (A-B) and triple negative (TNBC, C-D) were stained using biotinylated hJAA-F11 H2aL2a (A, C) or a
biotinylated human myeloma IgG protein (B, D). The background staining differences were also assessed in normal esophagus (E-H) and
kidney (I-L) using the biotinylated human antibodies (E-F, I-J) and the mouse JAA-F11 and control mouse IgG3 antibodies (G-H, K-L). These
images indicate that hJAA-11 H2aL2a does not bind to normal human esophagus or kidney. Experiments were done in parallel, and color
development was identical for all slides. Magnification: 40×.
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mouse JAA-F11. Glycan array analysis has documented the highly
lective chemical specificity of JAA-F11 and its humanized derivatives
r the tumor-associated TF-Ag-α [52,69]. The high specificity of JAA-
1 for TF-Ag-α is due to its ability to recognize TF-Ag through cavity-
pe glycan binding rather than themore one-sided groove-type antigen
cognition. Computational analysis of JAA-F11 revealed that the
ino acid composition of JAA-F11’s light chain variable region does
t allow for the binding to the TF-Ag-β structure while allowing the
ecific binding to the tumor-associated TF-Ag-α presentation [69].
herefore, JAA-F11 represents a strong and specific tool for the
munohistochemistry-based assessment of TF-Ag–bearing human
rcinomas and future cancer therapeutic applications. Importantly, the
C and in vivo biodistribution and imaging studies also document the
mor-specific binding of hJAA-F11 H2aL2a, with limited or no
nding to normal tissues, supporting its preclinical development for
ncer immunotherapeutic applications.
Imaging and biodistribution results with radiolabeled hJAA-F11
2aL2a in themouse tumormodels for both breast and lung cancers also
pport the specificity of humanized JAA-F11 in vivo. While the mouse
A-F11 did have some IHC reactivity that may be specific against some
rmal tissue sections from stomach and pancreas, this staining may be
e to enzymatically degraded postmortem tissue, and this is supported
the lack of accumulation in stomach and liver in the biodistribution
alysis. Furthermore, the differences in tumor retention of the labeled
tibody compared to the time course of retention in all other organs
nfirm that humanized JAA-F11 was not retained in any normal organ
amined. These findings combined with the lower background of theotinylated hJAA-F11 H2aL2a of IHC normal tissues suggest that
AA-F11H2aL2a or other humanized constructs of JAA-F11 are strong
ndidates for both theranostic and therapeutic uses.
onclusion
conclusion, this study highlights the therapeutic potential of JAA-
1 and its humanized derivative, hJAA-F11 H2aL2a, through broad
mor specificity analysis by IHC and radioimmunolocalization in
east and lung tumors in mouse models. Other studies are underway
r the preclinical analysis of humanized anti–TF-Ag antibodies
pporting their use in direct immunotherapy, antibody-drug
njugate therapy, or bispecific applications as well as in theranostic
es across a wide array of cancers reactive for JAA-F11. JAA-F11 and
manized variants hold great promise with reactivity with 85% of
69 cases of breast, lung, prostate, colon, ovarian, and bladder
ncers. This pancarcinoma reactivity is especially important for
ncers with a large unmet need such as TNBC as well as lung
ncers. With such a high degree of reactivity in different tumor
pes, prescreening prior to treatment may not be necessary, but if
sired, a multistep theranostic approach, with IHC analysis of tumor
nding followed by imaging, could help determine in vivo targeting
ior to immunotherapy or antibody drug conjugate therapy.
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Figure 12. micro-PET immunolocalization of hJAA-F11 H2aL2a in murine models of breast and lung cancers. Representative coronal plane
microPET 18F-FDG images (A) were obtained 1 hour postinjection (first column) in Balb/c mice containing 4T1 mammary tumor (B).
Representative coronal plane micro-PET scans (tracer is 124I- hJAA-F11 H2aL2a) of Balb/c mice either in the presence (C) or absence (D) of 4T1
mammary tumors. Representative coronal planemicro-PET scans (tracer is 124I hJAA-F11 H2aL2a) (F) of nudemice containing HTB-171 human
lung tumor xenografts (E). Tumor indicatedby arrow (C, F). Thehot spot above the tumor in early timepoints is thebloodpool circulating antibody
that is in the heart. This is supported by quantitative biodistribution analysis of blood in the “C” group that found 12.2% of the injected dose
remained in each ml of blood at 72 hours, 8.3% per ml of blood at 96 hours, and 0.18% per ml of blood at 168 hours (Figure 13).
Figure 13. Biodistribution of 124I hJAA-F11 H2aL2a in murine model of
breast cancer. Following imaging in Figure 12, mice were sacrificed,
indicated organs and tumors were weighed, and the amount of
radioactivity was quantified in a gamma-counter with appropriate
calibration. Radioactivity uptake was calculated as the percentage of
the injected dose per gram of tissue (%ID/g). The total administered
radioactivitywasdeterminedbymeasuring thesyringesbefore andafter
injection with a CRC-12R dose calibrator. The percentage of injected
dose (%ID) was corrected utilizing two accompanying standards at the
time of each biodistribution analysis.
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